Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 44 Sep 25 – Oct 24, 2026
- Disclosed funding
- $1.8B 28 disclosed amounts
- Median round
- $24.5M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| ST Star TherapeuticsCompany profile Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need. Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need. | $200M | Private financingUndisclosed | Biotech | United States | Investors | |
| PA Pathos AICompany profile Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials. Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials. | $237M | Series ESeries C+ | Biotech | United States | Investors | |
| WS Warp SciencesCompany profile Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States. Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States. | $215M | Series A | Biotech | United States | Investors | |
| S SEGNOSCompany profile SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing. SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing. | Undisclosed | Pre-Series AUndisclosed | Biotech | Japan | Investors | |
| i iCUREXCompany profile Kagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing. Kagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing. | ¥140M | Series A first close: equity and debtSeries A | Biotech, Healthtech | Japan | Investors | |
| W WarhoundCompany profile Warhound develops working dogs for military, law-enforcement and emergency-response teams. Warhound develops working dogs for military, law-enforcement and emergency-response teams. | $200M | Seed | Biotech, Defense tech | United States | Investors | |
| K Rice-based dairy alternatives and plant molecular-farming technology. | ¥490M | Series A first closeSeries A | Biotech, Foodtech | Japan | Investors | |
| N Clinical-stage biotech developing neoantigen-based cancer immunotherapies. | €120M | Series DSeries C+ | Biotech | Switzerland | Investors | |
| M MicrobioticaCompany profile Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment. Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment. | £36M | Series C first closeSeries C+ | Biotech | United Kingdom | Investors | |
| EB Estuary BiotherapeuticsCompany profile Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease. Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease. | $93M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Sep 25, 2026
- 1Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
3rounds1led - 24BIO Capital
Estuary Biotherapeutics, Undecimal Bio, Aptadir Therapeutics
3rounds2led - 3Novo Holdings
OMass Therapeutics, AnaCardio, Breye Therapeutics
3rounds3led - 4Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
3rounds0led - 5Breyer Capital
Warhound, Soufflé Therapeutics
2rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →